City Investors Circle is an established group of investors focused on growth companies in their early stages of development.
If you actively manage your own investment portfolio, and are interested in meeting the CEO’s of exciting growth companies, email rhea@city-investors-circle.com to register your interest in attending future meetings.
Scorpio Gold Corp. {TSX.V: SGN} surprised the market by announcing that the recently announced $15 million financing with NY based Coral Reef Capital LLC has been terminated.
This follows concerns expressed by certain large shareholders, and will result in Scorpio having to pay a termination penalty fee. Continue reading
Vancouver, B.C. – Apr 27, 2015) – Scorpio Gold Corporation {TSX.V: SGN} announces the commencement of underground exploration drilling, and results from its 2014 surface drilling program, at the Company’s 100% owned Goldwedge project, located in Manhattan, Nevada. Continue reading
Inovio Pharmaceuticals {NASDAQ: INO} have ,according to legal website Law360, been in receipt of a complaint from the former managing director of a pharma company they merged with in 2009.
The complaint was filed in a New Jersey Court.
Scorpio Gold {TSX.V: SGN} sets a Quarterly Production Record at their Mineral Ridge Operation, Nevada.
With production of 11,952 ounces of gold in the first quarter, Scorpio Gold exceeded the first quarter 2014 by some 16%. Silver production increased by some 23% over the same period. Continue reading
Content here…..
Scorpio Gold {TSX.V:SGN} report BLM approval for their amended plan of operations for their Mineral Ridge deposit, located in Nevada.
This allows mining of the previously unmined Bluelite and Solberry pits. Continue reading
Inovio Pharmaceuticals {NASDAQ: INO} and Roche are to Initiate Clinical Trials for Inovio’s DNA Immunotherapy To Treat Chronic Hepatitis B Infection
This trial triggers a $3 million milestone payment to Inovio from Roche as part of their 2013 agreement to jointly develop INO’s Hepatitis B immunotherapy. Continue reading
Nymox Pharmaceutical {NASDAQ: NYMX} today announced new results from the company’s latest phase 2 trials for it’s NX-1207 prostrate cancer study.
CEO Paul Averback The company were pleased to note the new results demonstrate “the potential of NX-1207 to offer men with the most common form of low-grade prostate cancer a significant tangible benefit ” Continue reading
City Investors Circle announce an evening investor presentation with a mining theme in London on Wednesday April 22nd.
For full details and registration, please email – Rhea@city-investors-circle.com
Terrace Energy reports additional well results and continuing progress on its STS Olmos Development Project.
COO George Morris “pleased with the results of our six wells”
City Investors Circle are running an evening presentation with a mining theme next Tuesday, 21st April, in the financial district of the City of London.
The evening commences at 18.00 for 18.30, and the presentation will be followed by complimentary wines and a selection of wonderful hot and cold canapes. Continue reading
El Niño Ventures Inc. {TSX.V: ELN} and African Investments Ltd. announce a termination of their agreement by mutual consent.
The long running saga involving El Niño’s DRC assets at Kasala continues, a solution seems as far away as ever.
The scheme of arrangement agreed gives a premium of 51% to the recent price of Soltoro’s shares, and also gives shareholders shares in a new company, “spinco”, to be floated and given to Soltoro’s shareholders.
Inovio Pharmaceuticals {NASDAQ: IMO} HPV Immunotherapy Activates Robust In Vivo T Cell Responses in Head & Neck Cancer Patients
DNA-based immunotherapy generates strong immune responses similar to those in patients treated for cervical dysplasia
Scorpio Gold {TSX.V: SGN} has released the final drill holes from their 2014 drill program a Solberry Satellite Deposit, located at their Mineral Ridge project in Nevada.
The RC drill holes encountered some high grade mineralisation, and indcate the potential to increase the LOM. Continue reading
Inovio Pharmaceuticals {NASDAQ: INO} has been selected by DARPA to Lead a $45 Million Program to Expedite Development of Novel Products to Prevent and Treat Disease Caused by Ebola.
Funding Will Accelerate Development of Inovio’s DNA-Based Monoclonal Antibodies That Could Offer Product Development, Manufacturing, Scale-Up and Dosing Benefits
Inovio Pharmaceuticals {NASDAQ: INO} presented at the prestigious Piper Jaffray sponsored 3rd annual Regenmed investor conference in New York City.
This video of the presentation, was made to the conference on the 25th March 2015, and features COO Niranjan Sardesai.
The shareprice of NYMOX Pharmaceutical {NASDAQ: NYMX} has virtually tripled in the past week!
News released on Wednesday that NYMOX are continuing further analysis for Phase 3 studies does not seem good enough on its own to support such a parabolic rise.
Neometals [ASX: NMT] confirmed it had receives and Australian Stock Exchange inquiry into the recent price and volume of the company’s stock.
